AstraZeneca Commits $100 Million To MedImmune Ventures
This article was originally published in The Pink Sheet Daily
The UK-based pharma’s corporate venture arm now has $400 million under management in an evergreen fund, with an expanded global focus that includes health care information technology.
You may also be interested in...
Based on research from the University of North Carolina and seeded by Hatteras Venture Partners, the start-up is developing cyclin-dependent kinase (CDK) 4/6 inhibitors for use in protecting the bone marrow of cancer patients receiving chemotherapy. The funding should bring the biotech through IND filing and into Phase I work.
As traditional venture-like returns are harder to generate from drug development and medtech plays, some frustrated VCs see new opportunities in health care information technology, an area many have traditionally avoided.
New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.